Last reviewed 2026-04-20 · How we verify

Omidria

Silverstein Eye Centers · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Omidria
Sponsor	Silverstein Eye Centers
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
No Drop Post-Op Cataract Surgery (PHASE4)
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery (PHASE4)
Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain (PHASE4)
Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results